Pure Global
NCT04201275

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects

A Single-center, Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Consecutive Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of HEC74647 in Subjects With Chronic Hepatitis C Virus Infection
Sunshine Lake Pharma Co., Ltd.·Phase 1·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chronic Hepatitis C
Drug/Device/Intervention
HEC74647PA capsule
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sunshine Lake Pharma Co., Ltd.
Location
Changchun, China
Timeline & enrollment
Phase
Phase 1
Start date
Dec 18, 2019
End date
Jan 21, 2020
Enrollment
28 participants
Primary outcome

Adverse Events,laboratory abnormalities and other abnormalities,Antiviral Activity,Sequence changes in the NS5A coding region,Cmax,Tmax,AUC,t1/2

Summary

The goal of this study is to assess the tolerability, pharmacokinetics and antiviral activity
 of HEC74647 in HCV treatment naïve subjects with genotypes 1-6.

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic viral hepatitisOther chronic viral hepatitisChronic hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04201275
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04201275 through Pure Global AI's free database. This Phase 1 trial is sponsored by Sunshine Lake Pharma Co., Ltd. and is currently Completed. The study focuses on Chronic Hepatitis C. Target enrollment is 28 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.